Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01598324 · ClinicalTrials.gov registry record
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
A clinical trial, sponsored by Mclean Hospital.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01598324 is a clinical trial that was terminated before completion, run by Mclean Hospital. The registered enrollment target is 1 participants.
The verdict
NCT01598324 was terminated before completion, sponsored by Mclean Hospital.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for treatment-resistant depression (NCT00633399). This observational study will involve magnetic resonance scans to examine brain chemistry (neurotransmitter levels), brain activity, and functional connections between brain regions before and after participating in the trial. The neurotransmitters of interest are glutamate, glutamine, and GABA. Comparisons will be made between individuals who receive ziprasidone and individuals who receive an inactive placebo. Differences between participants who respond to standard antidepressants and those who require additional medication will also be examined. All participants will have a baseline magnetic resonance scan before starting medication. The second scan will be after 8 weeks of escitalopram treatment for those who respond or following 8 weeks of escitalopram plus ziaprasidone or placebo (16 weeks after starting) for those who do not respond to escitalopram alone. Participants will complete standard rating scales for depression at each visit.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01598324
The ClinicalTrials.gov registry entry for NCT01598324 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01598324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01598324 about?
NCT01598324 is a clinical study titled "Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder". This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for treatment-resistant depression (NCT00633399). This observational study wil...
What is the current status of trial NCT01598324?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2012-07.
Who is sponsoring clinical trial NCT01598324?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.